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Somatic Mutations in Paroxysmal Minireview
Nocturnal Hemoglobinuria:
A Blessing in Disguise?
Lucio Luzzatto, Monica Bessler, and Bruno Rotoli* PNH Arises through a Somatic Mutation
in an X-Linked GeneDepartment of Human Genetics
Memorial Sloan Kettering Cancer Center This set of remarkable features led to the notion that
PNH might arise through a somatic mutation in a multi-1275 York Avenue
New York, New York 10021 potent hematopoietic stem cell. In support of this notion,
the PNH red cells of women heterozygous for two elec-*Permanent address:
Division of Hematology trophoretically distinguishable alleles of the X-linked
gene encoding glucose 6-phosphate dehydrogenaseFederico II University Medical School
Via S Pansini 5 were found all to express the same allele, indicating that
they belonged to one clone (Oni et al., 1970). Subse-80100 Napoli
Italy quently, extensive characterisation of the abnormal
cells—which we will refer to for brevity as PNH cells—
revealed that several membrane proteins were deficient
(Davitz et al., 1986), including CD55 (which inhibits theNames given by physicians to human ailments range
formation of or destabilizes the C3 convertase), andfrom the esoteric to the simplistic, and they may provoke
CD59 (which protects the membrane from attack byin the non-physicians anything from intimidation to in-
the C5–C9 complex of activated C). While this findingcredulity, but probably very few are as picturesque
provided a gratifying explanation for the hypersuscepti-as paroxysmal nocturnal hemoglobinuria. In addition,
bility to C of PNH red cells (Davitz et al., 1986; see otherwhereas medical terms do not always adhere to the
references in Kinoshita et al., 1995), several puzzlingmeaning that words have in plain English (a “benign”
questions emerged. First, the presence of multipletumor can kill if it is in the brain, while “pernicious”
abnormalities seemed to be in conflict with the notionanemia can be quickly reversed by one shot of vitamin
of a single somaticmutation. Second, if a single mutationB12), the phrase paroxysmal nocturnal hemoglobinuria
gives the PNH phenotype, it is by definition a dominant(PNH) describes very accurately the telltale sign of this
mutation. This would not seem in keeping with a defectcondition. Indeed, the patient may be a child or an old-
in a biosynthetic enzyme, since nearly all enzyme defi-age pensioner, a male or a female, may be from any
ciencies are recessive. Third, if the mutated clone ex-part of the world, and may have been always well, until
pands to the point of accounting for a substantial pro-she or he wakes up one morning to the rather unpleasant
portion of hematopoiesis (usually z50% and oftensurprise that the urine has turned intensely dark, as
more), it must mean that at some point it has grownthough it contained blood. In fact, it contains hemoglo-
faster than the average normal hematopoietic cells, abin released from massive destruction of red cells within
rather surprising implication for a clone whose cells arethe bloodstream, and hence filtered through the renal
in fact hypersusceptible to C, and thus, crudely speak-glomeruli. Thus, in the jargon of hematologists, PNH is
ing, are disabled rather than overbearing (see Rotoli andclassified as a hemolytic anemia in which hemolysis is
Luzzatto, 1989; Luzzatto and Bessler, 1996).intravascular (Dacie, 1967; Lee, 1993).
A possible solution to the first paradox came quicklyPNH is a rare disease, and although there are no
into sight, thanks to the remarkable finding that all theprecise data on its prevalence in the population, it has
surface molecules deficient in PNH red cells (as well asbeen estimated that there are between one and ten
in white cells and platelets) belong to the class of pro-cases per million people. Yet, in about half a century,
teins that are anchored to the membrane through a gly-since a reliable diagnostic test was developed for this
can phosphatidyl inositol (GPI) anchor (Cross, 1987; Da-disease, we have witnessed the accumulation of a
vitz et al., 1986). Thus, it became tempting to imaginewealth of information, which can be drastically summa-
that the somatic mutation might have affected a steprized as follows (for references, see Luzzatto and Bess-
of the GPI biosynthetic pathway. To prove this byler, 1996). First, there is no evidence of increased inci-
biochemical studies on leukocytes proved more difficultdence within families; thus PNH is an acquired disorder.
than with hereditary metabolic defects, because in allSecond, the hemolysis is due to an intrinsic abnormality
patients the abnormal cells are always “contaminated”of red cells, which resides in their membrane and which
by residualnormal cells. Eventually, pure PNH cell popu-makes them hypersusceptible to the lytic action of acti-
lations were obtained by cellular cloning of EBV-trans-vated complement (C). Third, not all red cells have this
formed B lymphocytes, and by using appropriate la-abnormality: a variable but often substantial proportion
belled precursors in intact cells and in a cell-free system,appear to be entirely normal. Conversely, a proportion
a block was clearly identified at an early step of the GPIof other blood cells, including neutrophils, monocytes,
anchor biosynthesis: namely, the transfer of N-ace-platelets, and sometimes lymphocytes are also abnor-
tylglucosamine (NAcGl) from UDP-NAcGl to phosphati-mal. Fourth, the non-PNH blood cells are often reduced
dylinositol (see references in Luzzatto and Bessler,in numbers, suggesting that, although qualitatively nor-
1996). At about the same time, by a remarkable featmal, they are produced by a failing bone marrow. Indeed,
of expression cloning, Kinoshita’s group isolated fromPNH may arise in a patient who previously had severe
HeLa cells a cDNA by virtue of its ability to correctbone marrow failure, or aplastic anemia (AA), and some-
times a patient with overt PNH evolves to AA (Dacie, defective GPI biosynthesis in an in vitro mutagenized
cell line previously characterized by complementation1967).
Cell
2
Figure 1. Mutations in the PIG-A Gene Ob-
served in Patients with PNH
The cDNA structure shows the 6 exons, with
the codon numbers corresponding to the
exon–intron junctions given underneath. The
59 untranslated region (exon 1 and part of
exon 2) and the 39 untranslated region (part
of exon 6) are hatched. Below the cDNA dia-
gram are the mutations causing complete in-
activation of the gene product, including
small insertion-deletions producing frame
shifts (orange squares), nonsense mutations
(red squares), splice-site mutations (purple
lozenges), and large deletions (full black lines;
the broken line indicates that the breakpoints
of the large deletion removing the entire gene
are not known). Above the cDNA diagram are
missense mutations (blue circles) and one in-
frame deletion of a single codon (blue trian-
gle). The mutation in codon 19 (green circle)
is the only known PIG-A mutation that is
germ-line rather than somatic: it entails a Arg→Trp amino acid replacement. This mutation has been observed in four unrelated families and
it does not cause PNH; it is probably to be regarded as a neutral polymorphic allele. Frame shift and nonsense mutations appear to be rather
randomly spread, perhaps because protein truncation will cause instability or failure of targeting almost regardless of where it takes place.
By contrast, missense mutations are nearly always limited to exon 2, suggesting that this is a functionally critical domain. The mutations
shown here are from sources quoted in Luzzatto and Bessler (1996).
analysis as belonging to group A: hence the gene was Therefore we can surmise that there may be many more
missense mutations which do not give a PNH pheno-called Phosphatidyl Inositol Glycan A, or PIG-A (Miyata
et al., 1993; Takeda et al., 1993). It was then quickly type. Interestingly, insome patients,more than one inde-
pendently arisen PIG-A mutation is found, indicatingshown that the same cDNA also complemented EBV-
transformed PNH cell lines from PNH patients, and that that several different PNH clones may co-exist (Luzzatto
and Bessler, 1996).these same cells had mutations in their own PIG-A gene
(Takeda et al., 1993; Bessler et al., 1994). Last but not These findings give a satisfactory overall picture of
the origins and of thepathophysiology of the PNH clone.least, PIG-A maps to the X chromosome(Xp22.1; Takeda
et al., 1993). Although it has not yet been formally proven In a nutshell, a somatic mutation hits the single func-
tional PIG-A gene in a hematopoietic stem cell; if thethat PIG-A encodes an N-AcGl transferase, this finding
neatly swept away the second paradox: PIG-A defi- mutation is such that PIG-A is completely or nearly com-
pletely inactivated the progeny of the mutated cell willciency does behave as recessive in somatic cell hybrids,
but it appears dominant in normal somatic cells simply be deficient in GPI-linked proteins and therefore very
vulnerable to C-mediated lysis. In first approximation,because these are haploid with respect to the X chromo-
some. Unlike what applies to X-linked inherited dis- this sequence of events is reminiscent of what probably
happens with a mutation in a tumor suppressor gene,eases, which characteristically have a higher prevalence
in males, there is no significant gender preference in except for two important differences: here, we have only
one hit instead of two, because PIG-A is X-linked. Also,the case of PNH: this is not surprising since the acquired
somatic mutation of PIG-A takes place after X chromo- although patients with PNH may very rarely ultimately
develop leukemia (Dameshek, 1967), PNH itself is cer-some inactivation, when female cells are just as haploid
as male cells with respect to all X-linked genes, except tainly not a leukemia; on the contrary, the PNH clone
may persist for decades with little change in the clinicalthose that escape inactivation.
There are now more than 100 PIG-A mutations in the situation, and in some cases it may actually decrease
in size, with apparent spontaneous cure of the patientdatabase (see Figure 1), and a fairly clear pattern
emerges. With the majority of mutations it can be safely (Hillmen et al., 1995). In an evolutionary sense these two
points may be related, and indeed, to the best of ourpredicted that the PIG-A protein will be nonfunctional,
either through truncation resulting from a stop codon, knowledge, no bona fide tumor suppressor gene has
yet been mapped to the X chromosome. Perhaps theor from a frame shift due to small insertion/deletions,
or from a splicing defect. Three large deletions have reason is that, with a single hit creating a risk to produce
a tumor, possibly in pre-reproductive age, the geneticbeen reported, one of which removes the entire PIG-A
gene. Of the missense mutations, some may still make cost of having one there would be too high.
What Determines the Fate of a Non-Malignantthe protein nonfunctional, whereas others probably ac-
count for the previously recognized fact that in some Hematopoietic Clone?
We are now left with the third paradox unsolved: namely,cases GPI-linked protein deficiency on PNH cells is par-
tial rather than complete (Rosse and Dacie, 1966). Since how can a hematopoietic PNH clone expand? On one
hand, one might surmise that such a clone has an intrin-the GPI anchor is the final metabolic product of a path-
way in which PIG-A is a catalyst (Kinoshita et al., 1995), sic growth advantage; i.e., it is aggressive, just like a
leukemic clone. However, several lines of evidence mili-even a small fraction of the normal PIG-A activity may
still allow the production of a significant amount of GPI. tate against this notion. First, in patients with PNH, PNH
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present. In this respect, one cannot help noting that
much of the biochemical work on GPI-linked molecules
has sprung from the study of the variable surface
glycoprotein (VSG) of trypanosomes (Masterson et al.,
1989; Ferguson et al., 1988). In that instance, the func-
tional role of the GPI anchor seems clearly to consist
of making it easy for the parasite to shed its VSG coat
and thus evade immune attack by host antibodies
(Cross, 1990). In PNH cells there may be an advantage
for the cell in not having GPI-linked molecules on its
surface, in order to evade a different sort of immune
attack. Thus, PNH and AA might in fact give us a new
Figure 2. A Model for the Pathogenesis of PNH
handle for elucidating the functional role of GPI-linked
In this cartoon the dark red circles are normal hematopoietic stem molecules in mammalian cells which, in spite of a wealthcells, on which the green prongs represent GPI-linked surface mole-
of recent information (see in Cardoso-de-Almeida et al.,cules. The pink circles are stem cells in which a PIG-A mutation
1994), has remained rather elusive. In the meantime, weprevents insertion in the membrane of any of the protein molecules
that are normally GPI-linked. A black bracket symbolizes a hypothet- should consider that a PIG-A mutation may bea blessing
ical molecule which, upon binding to a GPI-linked protein, can cause in disguise, because it enables a patient who otherwise
damage to the stem cell. Panel 1 represents a normal bone marrow, would have AA to survive, although at the price of having
in which an occasional cell with a PIG-A mutation may exist. In PNH (Luzzatto and Bessler, 1996).
Panel 2, normal cells are suffering damage, whereas cells lacking
In conclusion, PNH shares with leukemias several fea-GPI-linked molecules (i.e., PNH cells) are not affected and may grow.
tures of clonal disorders and, since it can evolve to leu-At this stage the patient may manifest symptoms of bone marrow
failure (AA), and the PNH clone would be picked up by appropriate kemia, it may still teach us something about leu-
tests. In Panel 3, as a result of selection, the majority of stem cells kemogenesis. On the other hand, whereas leukemic cell
are PNH cells. At this stage the patient has overt PNH. If the PNH proliferation is, by definition,unconditionally aggressive,
clone had not grown, by this time the patient would have instead PNH cell proliferation is conditioned by the environment.
severe AA. Based on Rotoli and Luzzatto (1989).
In this respect PNH can be also seen as a remarkable
exception to the golden rule that in every disease pro-
clone(s) can co-exist for years or decades with appar- cess, no matter how protean, we ought to be able to
ently normal hematopoietic cells: thus, the PNH clone, pinpoint a single primary agent. It seems instead that
having expanded, does not take over (as a leukemic two different causes are required to give the clinical
clone would do). Second, patients who have had PNH phenotype of PNH: one (A) that we now fully understand,
for years may sometimes recover spontaneously; but namely a somatic mutation in the PIG-A gene; and one
the PNH clone is still present years after this self-cure (B) that we can only define as a specific mode of bone
has occurred (Hillmen et al., 1995). We infer that, when marrow failure. The implications of this by now testable
conditions change, the PNH clone not only stops ex- model are that A alone would produce PNH clones of
panding, but may actually regress in relation to non-PNH no clinical significance, which may be lurking in normal
hematopoietic cells. Third, in chimeric mice produced people, whereas B alone would give, of course, the clini-
by knocking out PIG-A in embryonic stem cells, the cal picture of AA. It is only when A and B co-exist in the
resulting PNH red blood cells, far from prospering, tend same person that we see the clinical phenotype of PNH.
to disappear rather quickly after birth (Kawagoe et al.,
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